{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:44:27Z","timestamp":1785761067399,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurotox Res"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12640-021-00390-6","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T07:02:58Z","timestamp":1625122978000},"page":"1418-1429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Brain Targeting and Toxicological Assessment of the Extracellular Vesicle-Packaged Antioxidant Catalase-SKL Following Intranasal Administration in Mice"],"prefix":"10.1007","volume":"39","author":[{"given":"Sarah H.","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sureka","family":"Selvakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Haney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Batrakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Kiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn N.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"390_CR1","doi-asserted-by":"crossref","unstructured":"Ambani LM, Van Woert MH, Murphy S (1975) Brain peroxidase and catalase in Parkinson disease. Arch Neurol","DOI":"10.1001\/archneur.1975.00490440064010"},{"key":"390_CR2","doi-asserted-by":"crossref","unstructured":"Batrakova EV, Kim MS (2015) Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release","DOI":"10.1016\/j.jconrel.2015.07.030"},{"key":"390_CR3","doi-asserted-by":"crossref","unstructured":"Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Organ J","DOI":"10.1097\/WOX.0b013e3182439613"},{"key":"390_CR4","doi-asserted-by":"crossref","unstructured":"Cipolla CM, Lodhi IJ (2017) Peroxisomal dysfunction in age-related diseases. Trends Endocrinol Metab","DOI":"10.1016\/j.tem.2016.12.003"},{"key":"390_CR5","doi-asserted-by":"crossref","unstructured":"Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH (2018) Mechanism of intranasal drug delivery directly to the brain. Life Sci","DOI":"10.1016\/j.lfs.2017.12.025"},{"key":"390_CR6","doi-asserted-by":"crossref","unstructured":"Fan Y, Chen M, Zhang J, Maincent P, Xia X, Wu W (2018) Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases. Crit Rev Ther Drug Carrier Syst","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018024697"},{"key":"390_CR7","doi-asserted-by":"crossref","unstructured":"Giordano CR, Terlecky LJ, Bollig-Fischer A, Walton PA, Terlecky SR (2014) Amyloid-beta neuroprotection mediated by a targeted antioxidant. Sci Rep","DOI":"10.1038\/srep04983"},{"key":"390_CR8","doi-asserted-by":"crossref","unstructured":"Giordano CR, Terlecky SR (2012) Peroxisomes, cell senescence, and rates of aging. Biochim Biophys Acta - Mol Basis Dis","DOI":"10.1016\/j.bbadis.2012.03.013"},{"key":"390_CR9","doi-asserted-by":"crossref","unstructured":"Gsell W, Conrad R, Hickethier M, Sofic E, Fr\u00f6lich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem","DOI":"10.1046\/j.1471-4159.1995.64031216.x"},{"key":"390_CR10","doi-asserted-by":"crossref","unstructured":"Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, Patel T, Piroyan A, Sokolsky M, Kabanov AV, Batrakova EV (2015) Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy. J Control Release","DOI":"10.1016\/j.jconrel.2015.03.033"},{"key":"390_CR11","doi-asserted-by":"crossref","unstructured":"Haney MJ, Zhao Y, Jin YS, Batrakova EV (2020) Extracellular vesicles as drug carriers for enzyme replacement therapy to treat CLN2 Batten disease: optimization of drug administration routes. Cells","DOI":"10.3390\/cells9051273"},{"key":"390_CR12","doi-asserted-by":"crossref","unstructured":"Hanson LR, Fine JM, Svitak AL, Faltesek KA (2013) Intranasal administration of CNS therapeutics to awake mice. J Vis Exp","DOI":"10.3791\/4440"},{"key":"390_CR13","doi-asserted-by":"crossref","unstructured":"Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S (2016) Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci","DOI":"10.3390\/ijms17020171"},{"key":"390_CR14","doi-asserted-by":"crossref","unstructured":"Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M (2014) A comprehensive overview of exosomes as drug delivery vehicles\u2014endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta - Rev Cancer","DOI":"10.1016\/j.bbcan.2014.04.005"},{"key":"390_CR15","doi-asserted-by":"crossref","unstructured":"Kalani A, Chaturvedi P, Kamat PK, Maldonado C, Bauer P, Joshua IG, Tyagi SC, Tyagi N (2016) Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol","DOI":"10.1016\/j.biocel.2016.09.002"},{"key":"390_CR16","doi-asserted-by":"crossref","unstructured":"Kalani A, Tyagi N (2015) Exosomes in neurological disease, neuroprotection, repair and therapeutics: problems and perspectives. Neural Regen Res","DOI":"10.4103\/1673-5374.165305"},{"key":"390_CR17","doi-asserted-by":"crossref","unstructured":"Khan AR, Liu M, Khan MW, Zhai G (2017) Progress in brain targeting drug delivery system by nasal route. J Control Release","DOI":"10.1016\/j.jconrel.2017.09.001"},{"key":"390_CR18","doi-asserted-by":"crossref","unstructured":"Koepke JI, Nakrieko KA, Wood CS, Boucher KK, Terlecky LJ, Walton PA, Terlecky SR (2007) Restoration of peroxisomal catalase import in a model of human cellular aging. Traffic","DOI":"10.1111\/j.1600-0854.2007.00633.x"},{"key":"390_CR19","doi-asserted-by":"crossref","unstructured":"Kohen R, Nyska A (2002) Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol","DOI":"10.1080\/01926230290166724"},{"key":"390_CR20","doi-asserted-by":"crossref","unstructured":"Nell HJ, Au JL, Giordano CR, Terlecky SR, Walton PA, Whitehead SN, Cechetto DF (2017) Targeted antioxidant, catalase\u2013SKL, reduces beta-amyloid toxicity in the rat brain. Brain Pathol","DOI":"10.1111\/bpa.12368"},{"key":"390_CR21","doi-asserted-by":"crossref","unstructured":"Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, Filip M (2016) Oxidative stress in neurodegenerative diseases. Mol Neurobiol","DOI":"10.1007\/s12035-015-9337-5"},{"key":"390_CR22","unstructured":"Patel Z, Patel B, Patel S, Pardeshi C (2012) Nose to brain targeted drug delivery bypassing the blood-brain barrier: an overview. Drug Invent Today"},{"key":"390_CR23","doi-asserted-by":"crossref","unstructured":"Pires A, Fortuna A, Alves G, Falc\u00e3o A (2009) Intranasal drug delivery: how, why and what for?. J Pharm Pharm Sci","DOI":"10.18433\/J3NC79"},{"key":"390_CR24","doi-asserted-by":"crossref","unstructured":"Southam DS, Dolovich M, O\u2019Byrne PM, Inman MD (2002) Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol - Lung Cell Mol Physiol","DOI":"10.1152\/ajplung.00173.2001"},{"key":"390_CR25","doi-asserted-by":"crossref","unstructured":"Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG (2010) A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther","DOI":"10.1158\/1538-7445.AM2011-4446"},{"key":"390_CR26","doi-asserted-by":"crossref","unstructured":"Terlecky SR (2012) Peroxisomes, oxidative stress, and inflammation. World J Biol Chem","DOI":"10.4331\/wjbc.v3.i5.93"},{"key":"390_CR27","doi-asserted-by":"crossref","unstructured":"Undyala V, Terlecky SR, Vander Heide RS (2011) Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury. Cardiovasc Pathol","DOI":"10.1016\/j.carpath.2010.06.011"},{"key":"390_CR28","doi-asserted-by":"crossref","unstructured":"Uttara B, Singh A, Zamboni P, Mahajan R (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol","DOI":"10.2174\/157015909787602823"},{"key":"390_CR29","doi-asserted-by":"crossref","unstructured":"Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol","DOI":"10.1016\/j.biocel.2006.07.001"},{"key":"390_CR30","doi-asserted-by":"crossref","unstructured":"Walsh KM, Courtney CL (1998) Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol Pathol","DOI":"10.1177\/019262339802600601"},{"key":"390_CR31","doi-asserted-by":"crossref","unstructured":"Wen Z, Yan Z, He R, Pang Z, Guo L, Qian Y, Jiang X, Fang L (2011) Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv","DOI":"10.3109\/10717544.2011.596583"},{"key":"390_CR32","doi-asserted-by":"crossref","unstructured":"Wood CS, Koepke JI, Teng H, Boucher KK, Katz S, Chang P, Terlecky LJ, Papanayotou I, Walton PA, Terlecky SR (2006) Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic","DOI":"10.1111\/j.1600-0854.2005.00358.x"},{"key":"390_CR33","unstructured":"Y\u00e1\u00f1ez-M\u00f3 M et al (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles"},{"key":"390_CR34","doi-asserted-by":"crossref","unstructured":"Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S (2015) Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio Rerio. Pharm Res","DOI":"10.1007\/s11095-014-1593-y"},{"key":"390_CR35","doi-asserted-by":"crossref","unstructured":"Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR (2008) Reactive oxygen species in tumor necrosis factor-\u03b1-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol","DOI":"10.1038\/jid.2008.122"},{"key":"390_CR36","doi-asserted-by":"crossref","unstructured":"Yuan D, Zhao Y, Banks WA, Bullock KM, Haney M, Batrakova E, Kabanov AV (2017) Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials","DOI":"10.1016\/j.biomaterials.2017.07.011"},{"key":"390_CR37","doi-asserted-by":"crossref","unstructured":"Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, Jiang J, Elgamal OA, Mo X, Perle K La, Chalmers J, Schmittgen TD, Phelps MA (2017) Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles","DOI":"10.1080\/20013078.2017.1324730"},{"key":"390_CR38","doi-asserted-by":"crossref","unstructured":"Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, Miller D, Zhang HG (2011) Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther","DOI":"10.1158\/1538-7445.AM2012-4831"}],"container-title":["Neurotoxicity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12640-021-00390-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12640-021-00390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T14:08:15Z","timestamp":1699193295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12640-021-00390-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1007\/s12640-021-00390-6","relation":{},"ISSN":["1029-8428","1476-3524"],"issn-type":[{"value":"1029-8428","type":"print"},{"value":"1476-3524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"6 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The recombinant enzyme CAT-SKL is covered by United States patent 7601366 and 8663630 to P.A. Walton and S.R. Terlecky, who have no commercial or equity interests in the CAT-SKL molecule at this time. Other authors state no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}